Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pantheon Resources replaces CFO after just nine months

(Sharecast News) - Pantheon Resources has appointed a new chief financial officer, with current CFO Phil Patman set to leave the Alaska-focused oil and gas company after just nine months in the role. Tralisa Maraj, the CFO of US-listed LiveWire Group and former CFO of Canada-listed CGX Energy, has been named as Patman's replacement.

The shake-up comes ahead of the oil and gas firm's transition from a pre-revenue AIM-listed company to a producer listed on a senior US exchange.

Patman, who had served as CFO of public companies VAACLO Energy and Soluna Holdings before joining Pantheon last September, was brought in to help the company prepare for a potential US listing.

In a statement, chief executive Max Easley thanked Patman "for his efforts in delivering a strong financial platform for growth through this transition and an ultimate US listing".

Pantheon also announced the appointment of former BP and Microsoft veteran Erich Krumanocker as its new chief development officer, with current CDO and original Pantheon founder Bob Rosenthal intending to retire at the company's AGM later this week.

"We are delighted to welcome Tralisa and Erich to the Pantheon executive team," Easley said.

"They will be key in enacting our pivot from a world class exploration and appraisal team to an equally successful development and operations team. Pantheon will benefit from a combined 50 years of international experience between the two."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.